Physician profile
Mark J Fast
NPI 1831173590
$5,899.85
in general payments reported to CMS, 2019-2025
14 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $233 · 2021: $1,096 · 2022: $481 · 2023: $998 · 2024: $550 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,792 · Consulting Fee: $1,070 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,792.49 |
| Consulting Fee | $1,070.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,186.85 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,364.05 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Coopervision INC. | $656.79 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Ortho-K Contact Lens |
| Sun Pharmaceutical Industries INC. | $567.60 | 2019-2024 | Cequa |
| Genentech USA, INC. | $373.54 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $320.28 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $111.07 | 2021 | |
| Rxsight INC | $97.04 | 2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Novartis Pharmaceuticals Corporation | $52.74 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $40.75 | 2023-2025 | Miebo, Xiidra |
| Oyster Point Pharma, INC. | $38.88 | 2023-2024 | Tyrvaya |
| Allergan, INC. | $34.34 | 2021-2022 | |
| Abbvie INC. | $32.09 | 2025 | |
| Biotissue Holdings INC. | $23.83 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.